Phase 3 Venous Thromboembolism (VTE) Clinical Trials

4 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–4 of 4 trials

Recruiting

Phase 3

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

Symptomatic Venous Thromboembolism (VTE)

Regeneron Pharmaceuticals2,000 enrolled14 locationsNCT07213778

Recruiting

Phase 3

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Venous Thromboembolism (VTE)

Regeneron Pharmaceuticals2,000 enrolled41 locationsNCT07015905

Recruiting

Phase 3

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

Venous Thromboembolism (VTE)Postpartum

Marc Blondon9,200 enrolled1 locationNCT07140211

Completed

Phase 3Phase 4

Assessment of microbleeding after prophylaxis with enoxaparin or rivaroxaban against venous thromboembolic disease following hip and knee surgery

Prevention and treatment of venous thromboembolism (VTE); comprising deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip and knee arthroplasty.

Launceston General Hospital1,060 enrolled1 locationACTRN12609000762257